Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CP-547632 TFA is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases with IC50 values of 11 nM and 9 nM, respectively. It demonstrates selectivity for VEGFR-2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs), exhibiting antitumor efficacy [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約8-10 週間 | ¥ 452,500 |
50 mg | 約8-10 週間 | ¥ 592,500 |
100 mg | 約8-10 週間 | ¥ 780,500 |
説明 | CP-547632 TFA is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases with IC50 values of 11 nM and 9 nM, respectively. It demonstrates selectivity for VEGFR-2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs), exhibiting antitumor efficacy [1]. |
ターゲット&IC50 | VEGFR2:11 nM, FGFR:9 nM |
In vitro | CP-547632 TFA (1-1000 nM; 1 hour) dose-dependently inhibits VEGF-induced VEGFR-2 phosphorylation, achieving an IC50 of 6 nM [1]. |
In vivo | CP-547632 TFA, when administered orally in doses ranging from 6.25 to 100 mg/kg/day over a period of 10-24 days, results in a dose-dependent suppression of tumor growth in Colo-205, DLD-1, and MDA-MB-231 xenografts [1]. A single oral dose of 50 mg/kg produces plasma concentrations exceeding 500 ng/ml for a duration of up to 12 hours [1]. |
分子量 | 646.43 |
分子式 | C22H25BrF5N5O5S |
CAS No. | 2805804-54-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CP-547632 TFA 2805804-54-8 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Inhibitor inhibitor inhibit